Ukhetho olukhethwayo lolawulo lwesicaphucaphu kunye nokuhlanza okubangelwa yichemotherapy (CINV). Isicaphucaphu kunye nokuhlanza okubangelwa yichemotherapy (CINV) sesinye sezona mpendulo zimbi zoyikekayo phakathi kwezigulana ezifumana unyango lomhlaza, nto leyo echaphazela kakhulu ukuthotyelwa konyango kunye nomgangatho wobomi. Njengesizukulwana esitsha se-NK1 receptor antagonists, iFosaprepitant Dimeglumine, eneempawu zayo ze-pharmacological zokukhetha okuphezulu kunye nobudlelwane obuphezulu, inokuthintela kakhulu indlela yokubonisa ukuhlanza elawulwa yi-substance P.
Idatha yeklinikhi iqinisekisa ukuba le mveliso inemiphumo emihle kakhulu yokulawula isicaphucaphu esibukhali nesilibazisekayo kunye nokuhlanza okubangelwa yi-highly emetogenic chemotherapy (HEC) kunye ne-moderate emetogenic chemotherapy (MEC). Ukuthathwa kwedosi enye kunokufezekisa i-antiemesis esebenza ixesha elide ngokunyamezela okuhle. Xa idityaniswe nee-5-HT3 receptor antagonists kunye ne-dexamethasone, yakha inkqubo yokukhusela i-CINV epheleleyo nepheleleyo.
Ukususela ekusetyenzisweni lula ukuya ekuzinzeni kokusebenza kakuhle, iFosaprepitant Dimeglumine inika ukhetho olungcono lwezonyango, inceda izigulane zidlule kumjikelo we-chemotherapy kakuhle kwaye zenze unyango lomhlaza lube novelwano ngakumbi.
Ixesha leposi: Disemba-09-2025
